EEElisa Schrader Echeverri

Elisa Schrader Echeverri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elisa Schrader Echeverri has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • James E. Dahlman

    Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA

    4 shared publications
  • Afsane Radmand

    Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, USA

    2 shared publications
  • Bart J. M. van Vlijmen

    Department of Internal medicine, division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands

    2 shared publications
  • Jeroen Eikenboom

    Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands

    2 shared publications
  • Noa A. Linthorst

    Department of Internal medicine, division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands

    2 shared publications
  • Richard J. Dirven

    Department of Internal medicine, division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands

    2 shared publications

Latest Publications

  • Open Access

    Tumor agnostic drug delivery with dynamic nanohydrogels

    by Stephen N. Housley, Alisyn R. Bourque, Lilya V. Matyunina, Isabel A. Panicker, Elisa Schrader Echeverri, Marrissa Izykowicz, Olivia A. Herrmann, Sebinne Lee, Johana C. Arboleda, Vida Jamali, et al.

    RNA interference (RNAi) holds unique potential as a clinically viable modality to pharmacologically regulate oncogenes in sequence-specific manner. However, systemic delivery of RNAi to tumors encounters myriad obstructions, and strategies to overcome such barriers have largely consisted of academic demonstrations with few approaches reaching patients. Here we report the development of a self-agglomerating nanohydrogel (SANGs) platform that selectively localizes to tumor tissue, is efficiently internalized by cancer cells, is agnostic to RNAi payload, and achieves functional suppression of multiple oncogene targets. After intravenous injection, SANGs preferentially accumulate and are retained in primary and metastatic loci in four aggressive cancer models in rodents. SANGs deliver multiple RNAi payloads that significantly suppress oncogene expression and sensitize previously resistant tumors while being safe and well tolerated in simulated clinical applications across three species. We propose, and provide the first direct evidence in support of, a mechanism featuring emergent material properties by which SANGs achieve durable solid-tumor delivery without attachment of cell- or tumor-targeting ligands. Overall, the SANGs platform is an enabling technology for RNAi-based cancer therapeutics and is poised for advanced pharmaceutical development with multiple solid-tumor indications.


  • Open Access

    Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses

    by Sebastian G. Huayamares, Liming Lian, Regina Rab, Yuning Hou, Afsane Radmand, Hyejin Kim, Ryan Zenhausern, Bhagelu R. Achyut, Melissa Gilbert Ross, Melissa P. Lokugamage, et al.

    Most cancer patients diagnosed with late-stage head and neck squamous cell carcinoma are treated with chemoradiotherapy, which can lead to toxicity. One potential alternative is tumor-limited conversion of a prodrug into its cytotoxic form. We reason this could be achieved by transient and tumor-specific expression of purine nucleoside phosphorylase (PNP), an Escherichia coli enzyme that converts fludarabine into 2-fluoroadenine, a potent cytotoxic drug. To efficiently express bacterial PNP in tumors, we evaluate 44 chemically distinct lipid nanoparticles (LNPs) using species-agnostic DNA barcoding in tumor-bearing mice. Our lead LNP, designated LNP intratumoral (LNPIT), delivers mRNA that leads to PNP expression in vivo. Additionally, in tumor cells transfected with LNPIT, we observe upregulated pathways related to RNA and protein metabolism, providing insight into the tumor cell response to LNPs in vivo. When mice are treated with LNPIT-PNP, then subsequently given fludarabine phosphate, we observe anti-tumor responses. These data are consistent with an approach in which LNP-mRNA expression of a bacterial enzyme activates a prodrug in solid tumors.


  • Open Access

    Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs

    by Noa A. Linthorst, Yvonne K. Jongejan, Richard J. Dirven, Sebastiaan N. J. Laan, Ruben Bierings, Caterina Casari, Robert A. Cordfunke, James E. Dahlman, Natasja Dolezal, Jan Wouter Drijfhout, et al.

    Treatment options for the bleeding disorder von Willebrand disease type 2B (VWD2B) are insufficient and fail to address the negative effects of circulating mutant von Willebrand factor (VWF). The dominant-negative nature of VWD2B makes functionally defective VWF an interesting therapeutic target. Previous in vitro studies have demonstrated the feasibility of allele-selective silencing of mutant VWF using small interfering RNAs (siRNAs) targeting common single nucleotide polymorphisms (SNPs) in the human VWF gene, an approach that can be applied irrespective of the disease-causing VWF mutation. This study aims to extend this concept to a heterozygous VWD2B mouse model (c.3946G>A; p.Val1316Met) here using mouse strain-specific genetic differences as proxy for human SNPs. Homozygous VWD2B C57BL/6J (2B-B6) mice were crossed with homozygous wild-type 129S1/SvImJ (129S) mice to create heterozygous 2B-B6.129S F1 offspring. These 2B-B6.129S mice were intravenously injected with endothelial-specific lipid nanoparticles loaded with the allele-selective siVwf.B6 or control and 96 hours later, lung Vwf messenger RNA, plasma VWF levels, and phenotypic characteristics were evaluated. Treatment with siVwf.B6 reduced total VWF levels by 50%, with an expected selective reduction in mutant VWF protein. This coincided with normalization of multimeric structure, improved VWF collagen binding/VWF antigen ratio, and normalized bleeding times in two-thirds of heterozygous 2B-B6.129S mice. Being a novel approach in the field of hemostasis, we proved, for VWD, in mice, the concept of selectively inhibiting a mutant dominant-negative allele with siRNAs targeting a single nucleotide variation rather than the disease-causing mutation. For dominant-negative VWD, this offers potential for a customized therapeutic strategy.


  • Open Access

    Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo

    by Yvonne K. Jongejan, Elisa Schrader Echeverri, Richard J. Dirven, Kalina Paunovska, Noa A. Linthorst, Annika de Jong, Johannes C. Wellershoff, Kim D. van der Gouw, Bart J. M. van Vlijmen, James E. Dahlman, et al.

    An imbalance in von Willebrand factor (VWF) may either lead to bleeding (von Willebrand disease, VWD) or thrombosis. Both disorders have shortcomings in the currently available treatments. VWF itself could be a potential therapeutic target because of its role in both bleeding and thrombosis. Inhibiting VWF gene expression through allele-selective silencing of VWF with small interfering RNAs (siRNAs) could be a personalized approach to specifically inhibit mutant VWF in VWD or to normalize increased VWF levels in thrombotic disorders without complete VWF knockdown. Therefore, we investigated a method to allele-selectively silence the VWF gene in mice as a therapeutic strategy. Fourteen candidate siRNAs targeting murine Vwf of either the C57BL/6J (B6) or the 129S1/SvImJ (129S) strain were tested in vitro in cells expressing B6- and 129S-Vwf for inhibitory effect and allele-selective potential. Together with a nonselective siVwf, 2 lead candidate siRNAs, siVwf.B6 and siVwf.129S, were further tested in vivo in B6 and 129S mice. Efficient endothelial siRNA delivery was achieved by siRNA encapsulation into 7C1 oligomeric lipid nanoparticles. Treatment with the nonselective siVwf resulted in dose-dependent inhibition of up to 80% of both lung messenger RNA and plasma VWF protein in both mouse strains. In contrast, the allele-selective siVwf.B6 and siVwf.129S were shown to be effective in and selective solely for their corresponding mouse strain. To conclude, we showed efficient endothelial delivery of siRNAs that are highly effective in allele-selective inhibition of Vwf in mice, which constitutes an in vivo proof of principle of allele-selective VWF silencing as a therapeutic approach.


  • Computational modeling of corneal and scleral collagen photocrosslinking

    by Brandon G. Gerberich, Amy J. Wood-Yang, Afsane Radmand, Lauren M. Nichols, Amir Hejri, Elisa Schrader Echeverri, Hannah G. Gersch, Mark R. Prausnitz